Manufacturers of the AsepticSure® Hospital Disinfection System, Medizone International, Inc. announced recently that medical instrument sterilization in autoclaves and absolute bactericidal kill for hospital room disinfection can be confirmed by the same biological indicators.
Biological indicators are believed to be the only process indicators that can directly monitor the lethality of a given cleaning process and recommended by the FDA for all autoclave usage. The best reference for routine quality assurance of hospitality sterilization has become a spore test strips. The FDA claims they should be utilized with each autoclave load.
Medizone has discovered in laboratory tests that the same spore test strips are inactivated, or killed, when placed in a room during an AsepticSure run. More than 25 runs have since been completed using two different commonly used types of spore test strips resulting in identical results. During the testing, spore test strips were placed under the beds, on the floor, on walls and behind objects and these were found to be completely deactivated 100% of the time. The findings strongly indicate that AsepticSure Hospital Disinfection System can now demonstrate via independent, internationally recognized testing processes, a level of decontamination previously not considered achievable outside of an autoclave.
The great part of hospital testing is that it proves that once isolation has been disinfected using the AspeticSure process, the “sick room cycle” is broken, and no new infections will be generated from that room for significant periods of time. This has proven true for MRSA, better known as staph infections, C.difficile and Pseudomonas aeruginosa. The AsepticSure Process is demonstrating a level of hospital room disinfection that has been so far unattainable within normal workflows, but still obtaining real reductions in new hospital disinfection system that can guarantee a greater than 6-log kill of infective pathogens throughout the entire room. Furthermore it can now independently verify it with the same testing products used to confirm instrument sterilization in autoclaves.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor Relations, Medizone International, Inc.
T: (415) 331-0202E: email@example.com
Gary Hanauer, Media Contact Medizone International, Inc.
T: (510) 686-1238
For more information, visit:http://www.medizoneint.com